Leukemia Research
Volume 36, Issue 3 , Pages 253-261, March 2012

What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?

  • Michael W. Deininger

      Affiliations

    • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    • Corresponding Author InformationCorresponding author at: University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope, Room 4280, Salt Lake City, Utah 84112-5550, USA. Tel.: +1 801 581 6363; fax: +1 801 585 0900.
    • ,
  • Paul Manley

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland

Received 14 July 2011; received in revised form 12 September 2011; accepted 19 September 2011. published online 13 October 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0145-2126(11)00461-9

doi:10.1016/j.leukres.2011.09.018

Leukemia Research
Volume 36, Issue 3 , Pages 253-261, March 2012

Article Tools

* Image Usage & Resolution